Cite
Adib E, Klonowska K, Giannikou K, et al. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clin Cancer Res. 2021;27(14):3845-3853doi: 10.1158/1078-0432.CCR-20-4548.
Adib, E., Klonowska, K., Giannikou, K., Do, K. T., Pruitt-Thompson, S., Bhushan, K., Milstein, M. I., Hedglin, J., Kargus, K. E., Sholl, L. M., Tsuji, J., Hyman, D. M., Sisk, A., Shapiro, G. I., Vargas, H. A., Harding, J. J., Voss, M. H., Iyer, G., & Kwiatkowski, D. J. (2021). Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3845-3853. https://doi.org/10.1158/1078-0432.CCR-20-4548
Adib, Elio, et al. "Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3845-3853. doi: https://doi.org/10.1158/1078-0432.CCR-20-4548
Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus KE, Sholl LM, Tsuji J, Hyman DM, Sisk A, Shapiro GI, Vargas HA, Harding JJ, Voss MH, Iyer G, Kwiatkowski DJ. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clin Cancer Res. 2021 Jul 15;27(14):3845-3853. doi: 10.1158/1078-0432.CCR-20-4548. Epub 2021 Mar 16. PMID: 33727259; PMCID: PMC8282751.
Copy
Download .nbib